Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 127Terminated 29Recruiting 27Unknown 21Active not recruiting 16Withdrawn 9Not yet recruiting 3Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 16Nivolumab 10Paclitaxel 9Cisplatin 9Gemcitabine 8Bevacizumab 8venetoclax 7Vincristine 7Prednisone 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Taxes 5Surgical Procedures, Operative 5Rituximab 5Oxaliplatin 5Irinotecan 5Everolimus 5Capecitabine 5fludarabine phosphate 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Panitumumab × Clear all
NCT01088620 2013-03-14

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Suspended
134 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡